WO2002024675A1 - Process for manufacturing simvastatin and the novel intermediates - Google Patents

Process for manufacturing simvastatin and the novel intermediates Download PDF

Info

Publication number
WO2002024675A1
WO2002024675A1 PCT/IN2000/000088 IN0000088W WO0224675A1 WO 2002024675 A1 WO2002024675 A1 WO 2002024675A1 IN 0000088 W IN0000088 W IN 0000088W WO 0224675 A1 WO0224675 A1 WO 0224675A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
hydroxy
oxy
napthyl
intermediate compound
Prior art date
Application number
PCT/IN2000/000088
Other languages
French (fr)
Inventor
Ganesh Sambasivan
Original Assignee
Biocon India Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon India Limited filed Critical Biocon India Limited
Priority to AU2001228796A priority Critical patent/AU2001228796A1/en
Priority to PCT/IN2000/000088 priority patent/WO2002024675A1/en
Publication of WO2002024675A1 publication Critical patent/WO2002024675A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Definitions

  • the present invention utilizes a secondary amine, it results in a Lovastatin amide which does not contain any hydrogen in the amine nitrogen.
  • the Lovastatin amide requires lesser equivalents of lithium amide base and thus increases the cost effectiveness of the route.
  • lovastation following protection is reacted with a diamine (secondary amine).
  • the amide thus prepared is dissolved in dry tetrahydrofuran and cooled to -45°C to -20°C.
  • the metal amide base is prepared by adding n-BuLi to pyrrolidine and is cooled to -45°C to -20°C. After about 1 hour, the alkyl halide, methyl iodide, is added and the contents are stirred for 30min. Water is addeTTto the reaction mixture and the layers ⁇ a eQ aK 1 separated. The organic layer is washed with brine solution and concentrated under reduced pressure to give an oily residue, which contains the intermediate (IV or VI). The crude intermediate is then hydrolyzed to give the free acid which is converted to the ammonium salt and is cyclized to give the final product, simvastatin.
  • the aqueous layer was re-extracted with ethyl acetate and the combined organic layer was washed with water to neutral pH.
  • To the organic layer 3mL of methanol was added and cooled to 10°C. NH 3 gas was bubbled until the precipitation was complete. The mixture was stirred for 30 mTn at 10 U C and filtered. The solid was washed with 5 mL of acetone and the product was dried to get the crude product.
  • the crude product was suspended in water and ethyl acetate was added.
  • the layers were separated and the aqueous layer was re-extracted with ethyl acetate.
  • the combined organic layer was diluted with methanol and the temperature was brought to 20- 23°C.
  • a solution of ammonium hydroxide was added slowly. The mixture was stirred for 1 hour to get complete precipitation and filtered. The precipitate was washed with ethyl acetate and dried to afford the pure product.
  • the purified ammonium salt was dissolved in 75mL of toluene and heated to 100°C under constant sweep of nitrogen for 6hours. The solution was cooled to 25°C and 1 .25g of activated charcoal and 1.25g of neutral active alumina was added. The mixture was agitated for 30 min. and filtered through celite. The celite pad was washed with toluene (12.5mL). The filtrate was concentrated under reduced pressure to afford a syrup. The syrup was diluted with ethyl acetate and 50 ml of petroleum ether (boiling range 60°C to 80°C) was added. The solution was left for aging for 30 min at 23-25 u C. The precipitate obtained was filtered and the solid was washed with petroleum ether and dried at 40°C for 2hours to get the product, simvastatin.
  • the crude product, (3.5g) was dissolved in methanol (20mL) and 1.25g of activated charcoal was added and stirred for 30min. the mixture was filtered through a celite pad and the celite pad was washed with methanol. To the filtrate water was added slowly till crystallization sets in. The contents were stirred for 0.5h and water (24mL). The contents were stirred for lh and cooled to 15°C. The precipitate was filtered and the solid was washed with 20%o aqueous methanol (l OmL). The solid obtained was dried at 50°C for 4 hours under vacuum to afford the pure title product. The simvastatin obtained was of pharmaceutical grade.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This invention describes the synthesis of simvastatin from lovastatin by protecting the hydroxy group of the lactone ring and then converting to lovastatin amide using an amine and subsequent reaction with a metal amide base generated from n-butyl lithium and pyrrolidine and followed by treatment with methyl iodide to give desired C-methylated intermediate. This intermediate was further transformed to the final product, simvastatin. This method of production consumes lesser quantities of metal amide, gives fewer side reactions and a lowered overall cost of manufacture of simvavastin than other procedures reported.

Description

PROCESS FOR MANUFACTURING SIMVASTATIN AND THE NOVEL INTERMEDIATES
This invention relates to a process for manufacturing simvastatin and the novel intermediates.
BACKGROUND
The naturally occurring compounds of formula I and their semi-synthetic analogs are very active antihypercholesterolemic agents that function by limiting the cholesterol biosynthesis by inhibiting the HMG-CoA reductase enzyme. Compounds of formula I, include the natural fermentation products like mevinolin (disclosed in US Pat No. 4,231 ,938 and also known as lovastatin), compactin (disclosed in US Pat No. 3,983,240) and a variety of semi-synthetic and totally synthetic analogs thereof, all having the natural 2-methylbutyrate side chain. Compounds of formula V, having a 2,2-dimethylbutyrate side chain (e.g., simvastatin) are known to be more active inhibitors of HMG-CoA reductase than their 2-methylbutyrate analogs and thus of greater utility in the treatment of artherosclerosis, hyperlipemia, familial hypercholesterolemia and similar disorders.
The introduction of simvastatin (V) into the market as a more potent HMG- CoA reductase inhibitor than lovastatin (I) has provided a need for a high yielding process which is more economically efficient and environmentally sound than those have disclosed in the prior art.
Compounds of formula V (e.g. simvastatin) with the 2,2-dimethylbutyrate side chain and processes for their preparation are disclosed in U.S. Pat No. 45444 84 and EPO patent specification No. 33538. The route described are both tedious and cumbersome and gives very poor over all yields.
Simvastatin has also been prepared by the α-alkylation of the ester moiety as described in U.S. Patent Nos. 4,582,915 and 4,820,850.
U.S. Patent No. 4,582,915 discloses the direct methylation in a single step using a metal alkyl and a methyl halide. The process suffers from poor conversion coupled with many STOe reactions which complicate both isoll iόn and purification oξtjie final product, simvastatin.
The U.S. patent No. 4,820,850 describes a good conversion to simvastatin using a single charge of the amide base and alkyl halide. However, the process suffers from a large number of steps and hence affecting the over all yield. Further, the process utilizes a highly expensive silylating agent to protect the hydroxyl groups thus rendering the route cost ineffective.
Recent patents like U.S. Patent No. 5,763,653 and 5,763,646 describe the synthesis of the simvastatin from mevinolinic acid or the salt of mevinolinic acid as the starting material. US Patent 5,763,653, which describes the synthesis of simvastatin from the lovastatin amide, prepared by treating lovastatin or the salt of mevinolinic acid with primary amine like propyl amine. The resulting lova amide has a hydrogen in the amide nitrogen which reacts with Lithium amide base thereby necessitating the need for larger equivalent of the amide base. Furthermore, the hydrogen in the amide nitrogen can react with the methyl iodide and lithium amide base and thus lead to side reactions and thereby lowering the overall yield.
International Application WO 98/32751 , also describes a process for the manufacture of simvastatin, wherein lovastatin is treated with an amine to afford the amide. The amide is subsequently converted to its acetal, which taken up for the alkylation step.
These processes suffers from the fact that a primary amine is used for the ring opening and hence requires additional equivalent of the amide base reagent and suffers from other side reactions. Accordingly the objects of the present invention is to overcome the aforesaid drawbacks by increasing the overall yield and the purity of the product and also to avoid the protection-deprotection of the hydroxy groups obtained from the lactone ring opening using highly expensive silyl or other protecting agents.
Another object of the invention is to minimize the cost of production of simvastatin by utilizing cheap raw materials and cost effective route for synthesis. Det/ailed description of the invention.
To achieve the said objective, the present invention relates to a process of manufacturing Simvastatin of formula V from Lovastatin characterized by the following steps: a. protecting the hydroxy group of the lactone ring of Lovastatin, b. converting the protected Lovastatin to Lovastatin amide by treating with an amine in an organic solvent, c. reacting the said lovastatin amide with metal amide base in tetrahydrofuran (THF) followed by treatment with alkyl halide and cooling the said mixture at a temperature ranging between -45°C to - 20°C till C-methylated intermediate compound is formed, d. subjecting the said intermediate compound to hydrolysis to obtain its free acid, e. converting the said free acid to its ammonium salt and cyclizing the said ammonium salt to obtain simvastatin. The organic solvent used is a polar or non-polar solvent and the alkyl halide is methyl iodide.
The protection of the hydroxy group in the lactone ring in step (a) is carried out using (RCO)20 wherein R is CF3 or CH3.
The protection of the hydroxy group in the lactone ring in step (a) is also carried out using RιR2R3SiCl wherein R R2 and R3 are selected from CH3 and t- Bu.
The mixture of lovastatin amide and metal amide base is cooled at — 30°C. The amine used in step (b) is R4R5NH wherein R4 and R5 is selected from cyclopropyl group, n-Bu, t-Bu, n-Pr or'H.
The amine in step (b) is also pyrrolidine or piperidine. The metal amide base in THF used is prepared by adding n-butyl-lithium to pyrrolidine and cooling at a temperature ranging between -45°C to -20°C. The novel intermediate compound of formula Ha is [1 S- [l^ιl )ha(R*),3alpha,7beta,8beta(2S:,:,4S*),8abeta]-l ,2,3,7,8,8a-hexahydro-3,7- dimethyl-8-[2-(tetrahydro-4-0-acetyl-6-oxo-2H-pyran-2-yl)ethyl]-l-naphthalenyl ester. The novel intermediate compound of formula lib is [1 S-
[l alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta]-l ,2,3,7,8,8a-hexahydro- 3,7-dimethyl-8-[2-(tetrahydro-4-0-trifluoroacetyl-6-oxo-2H-pyran-2- yl)ethyl]-l-naphthalenyl ester.
The novel intermediate compound of formula Via is [1 S- [lalpha(R*),3alpha,7beta,8beta( 2S*,4S*),8abeta]-l,2,3,7,8,8a-hexahydro-3,7- dimethyl-8-[2-(tetrahydro-4-0-TMS-6-oxo-2H-pyran-2-yl)ethyl]-l-naphthalenyl ester.
The novel intermediate compound of formula Vila is N-Propyl-7- [l ,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)- napthyl]-3(R)-hydroxy-5(R)-0-TMS heptanoic acid amide.
A novel intermediate compound N-Butyl-7-[ 1 ,2, 6,7, 8,8a(R)-hexahy dro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy~ 5(R)-0-TMS heptanoic acid amide of formula Vllb.
A novel intermediate compound N-Piperidinyl-7-[l,2,6,7,8,8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TMS heptanoic acid amide of formula Vila
A novel intermediate compound N-tert-Butyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy^ 5(R)-0-TMS heptanoic acid amide of formula Vlld. A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6,7, 8,8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyI}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TMS heptanoic acid amide of formula Vile.
A novel intermediate compound N-Cyclopropyl-7-[l,2,6,7,8,8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vllf. A novel intermediate compound N-tert-Butyl-7-[l ,2,6, ?8,8a(R)-hexahydro-
Figure imgf000006_0001
{2(S)-methylbutanoyl }oxy]-l (S)-napthyl]-3(R)-hydroxy- 5(R)-0-TBDMS heptanoic acid amide of formula Vllg.
A novel intermediate compound N-Piperidinyl-7-[ 1 ,2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-inethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vllh.
A novel intermediate compound N-Propyl-7-[ 1 ,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- 5(R)-0-TBDMS heptanoic acid amide of formula Vlli. A novel intermediate compound N-Butyl-7-[l,2,6,7,8,8a(R)-hexahydro-
2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- 5(R)-0-TBDMS heptanoic acid amide of formula VIIj.
A novel intermediate compound N-Propyl-7-[ 1 ,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- 5(R)-0-acetyl heptanoic acid amide of formula Ilia.
A novel intermediate compound N-Butyl-7-[l,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- 5(R)-0-acetyl heptanoic acid amide of formula Illb.
A novel intermediate compound N-Cyclopropyl-7-[l, 2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-acetyl heptanoic acid amide of formula IIIc.
A novel intermediate compound N-tert-Butyl-7-[ 1,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- 5(R)-0-acetyl heptanoic acid amide of formula Hid. A novel intermediate compound N-Piperidinyl-7-[ 1 ,2, 6,7,8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-acetyl heptanoic acid amide of formula Hie.
A novel intermediate compound N-Propyl-7-[l , 2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy- ■ 5(R)-0-trifϊuoroacetyl heptanoic acid amide of formula Illf. A novel intermediate compound N-Butyl-7-[l , 2,6,7, 8,o^R)-hexanydϊO~ 2(^ ,6(R)-methyl-8-[{2(S)-methylbutanoyl }oxy]-l (S)-napthyl]-3(R)-hydroxy- 5(R)-0-trifluoroacetyl heptanoic acid amide of formula lllg.
A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6,7, 8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula Illh.
A novel intermediate compound N-tert-Butyl-7-[ 1 ,2, 6,7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl }oxy]-l (S)-napthyl]-3(R)-hydroxy- 5(R)-0-trifluoroacetyl heptanoic acid amide of formula Illi. A novel intermediate compound N-Piperidinyl-7-[l ,2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula IIIj.
A novel intermediate compound N-Propyl-7-[ 1 ,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethyIbutanoyI}oxy]-l(S)-napthyl]-3(R)- hydiOxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVa.
A novel intermediate compound N-Butyl-7-[ 1 ,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVb.
A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2, 6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-naρthylj- 3(R)-hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVc.
A novel intermediate compound N-tert-Butyl-7-[ 1 ,2,6,7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-trifluoiOacetylheptanoic acid amide of formula IVd. A novel intermediate compound N-Piperidinyl-7-[l ,2,6,7, 8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVe.
A novel intermediate compound N-Propyl-7-[l,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVf. A novel interrWdiate compound N-Butyl-7-[ 1 ,2, 6,7,8, 3^R)-hexahydr o- 2(S ,6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl }oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVg.
A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6, 7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl }oxy]- l (S)-napthyl]- 3(R)-hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVh.
A novel intermediate compound N-tert-Butyl-7-[ 1 ,2, 6,7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVi. A novel intermediate compound N-Piperdinyl-7-[l ,2,6,7,8,8a(R)-hexahydro-
2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVj.
A novel intermediate compound N-Piperidinyl-7-[ 1 ,2, 6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy,5(R)-0-TMS heptanoic acid amide of formula Villa.
A novel intermediate compound N-tert-Butyl-7-[ 1,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-TMS heptanoic acid amide of formula VHIb.
A novel intermediate compound N-Cyclopropyl-7-[l , 2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy,5(R)-0-TMS heptanoic acid amide of formula VIIIc.
A novel intermediate compound N-Butyl-7-[l, 2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-TMS heptanoic acid amide of formula VHId. A novel intermediate compound N-Propyl-7-[ 1,2,6,7, 8, 8a(R)-hexahydro-
2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-TMS heptanoic acid amide of formula VHIe.
A novel intermediate compound N-Piperidinyl-7-[ 1,2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula Vlllf. A novel internTSdiate compound N-tert-Butyl-7-[l ,2,6,τ «,8a(R)-hexahydiO- 2(^),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl }oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula Vlllg.
A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6, 7,8, 8a(R)- hexahydro-2(S),6(R)-dimeth.yl-8(S)-[2,2-dimethylbutanoyl }oxy]- l (S)-napthyl]- 3(R)-hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula Villh.
A novel intermediate compound N-Butyl-7-[ 1 ,2,6,7, 8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula VHIi. A novel intermediate compound N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro-
2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula VIIIj.
The instant process involves only 4 steps to synthesis simvastatin (V). The intermediates avoid the formation of other side reactions with the amide base and methyl halide.
Furthermore as the present invention utilizes a secondary amine, it results in a Lovastatin amide which does not contain any hydrogen in the amine nitrogen. Thus the Lovastatin amide requires lesser equivalents of lithium amide base and thus increases the cost effectiveness of the route.
A so, the absence of the hydrogen in the amide nitrogen prevents side reactions and thereby resulting in purer products.
Additionally, because of the higher purity of the intermediate products, the downstream processing requires fewer purification steps, thus increasing the overall yield.
According to this invention lovastation following protection is reacted with a diamine (secondary amine). The amide thus prepared is dissolved in dry tetrahydrofuran and cooled to -45°C to -20°C. The metal amide base is prepared by adding n-BuLi to pyrrolidine and is cooled to -45°C to -20°C. After about 1 hour, the alkyl halide, methyl iodide, is added and the contents are stirred for 30min. Water is addeTTto the reaction mixture and the layers ό a eQ aK1 separated. The organic layer is washed with brine solution and concentrated under reduced pressure to give an oily residue, which contains the intermediate (IV or VI). The crude intermediate is then hydrolyzed to give the free acid which is converted to the ammonium salt and is cyclized to give the final product, simvastatin.
The present invention is explained with the help of schemes I and II and foregoing examples.
EXAMPLE I
Preparation of Lovastatin O-TBDMS amide of general formulae III and VII from intermediates of general formulae II and VI.
7-fl,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl} oxy]-l(S)-napthyI]-3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid. (Vlb)
To a solution of lovastatin (l OOg, 0.2475 mol) in DMF (di methyl formamide) (300 ml), imidazole (33.6g, 0.495 m, 2 eq) was added followed by TBDMS (tertiary butyl dimethyl silane) chloride (55.8g, 0.3712m, 1.5eq). The reaction mixture was stirred at 50°C for 7 hrs. After completion of reaction, the reaction mixture was cooled to 10°C. Methanol (7.5 ml) was added and reaction mixture was stirred for 30 min. Cyclohexane (3.2 L) was added and the organic layer was washed with 3x1 L 5% sodium bicarbonate solution. It was washed further with water and brine. The organic layer was dried and concentrated completely (128 g).
7-ll,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-I{2(S)-methylbutanoyI}oxy]- l(S)-napthyl]-3(R)-hydroxy-5(R)-0-acetyl heptanoic acid (Ila)
To a solution of lovastatin (25g, 0.06 mol) in dry DCM (di chloro methane ) (250 ml), pyridine (7.5 ml, 0.0928M, 1.5eq) was added followed by DMAP (4,N,N, dimethyl anflffo pyridine) (0.75, 0.0061 M, 0.1 eq). AWtic anl ydride (7ml, 0.D742M, 1 -2 eq) was added over 5 minutes at 0°C. The reaction mixture was stirred overnight at room temperature. After completion of reaction the reaction mixture was worked up to afford the product (20 g, 72%).
7-Il ,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-I{2(S)-methylbutanoyl}oxyJ- l (S)-napthyl]-3(R)-hydroxy-5(R)-0-trifluoroacetyl heptanoic acid (lib)
To a solution of lovastatin (25g, 0.06 mol) in dry DCM (250 ml), pyridine (7.5 ml, 0.0928M, 1.5eq) was added followed by DMAP (0.75, 0.0061M, 0.1 eq). Trifluoro acetic anhydride (9.6 ml, 0.06 mol, 1.1 eq) was added over 5 minutes at 0°C. The reaction mixture was stirred overnight at room temperature. After completion of reaction the reaction mixture was worked up to afford the product (25 g, 80 %).
N-PropyI-7-[l,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)- methylbutanoyI}oxy]-l(S)-napthyI]-3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide (Vlli)
To a solution of silyl derivative (5g, 0.01 mol) in THF (tetra hydro furan) ( 10ml), n-propylamine ( 10.6 ml, 0.13mol, 13.4 eq) was added at room temperature. The reaction mixture was stirred for 12h at 40°C. After completion of the reaction, the reaction mixture was worked up to afford the corresponding product (5g, 90%).
N-Piperidinyl-7-[l,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)- methy!butanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide (Vllh)
To a solution of silyl derivative (5g, 0.01 mol) in toluene (15ml), piperidine (12 ml, 0.13mol, 13.4 eq) was added at room temperature. The reaction mixture was stirred under reflux for 12h. After completion of the reaction, the reaction mixture was worked up to afford the corresponding product (5g, 80%). !N-Cyclopropyl-7-l^,6,7,8,8a(R)-hexahydro-2(S),6(R)-mWIiyl-8-[{2(S)- methylbutanoyI}oxy]-l (S)-napthyl]-3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide (Vllf)
To a solution of silyl derivative (5g, 0.01 mol) in THF ( 10ml), 5 eye lopropyl amine (4 ml, 0. 12mol, 13.4 eq) was added at room temperature. The reaction mixture was stirred for 12h at 40°C. After completion of the reaction, the reaction mixture was worked up to afford the corresponding product (4g, 85%).
N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)- lo methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-acetyl heptanoic acid amide (Ilia)
To a solution of acetyl derivative (5g, 0.01 mol) in toluene (200ml), n- propylamine (26 ml, 0.31 mol, 7eq) was added at room temperature. The reaction mixture was stirred under reflux for 12h. After completion of the reaction, the i s reaction mixture was worked up to afford the corresponding product (18g).
N-Piperidinyl-7-[l,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)- methyIbutanoyI}oxyJ-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-acetyl heptanoic acid amide (Hie) 0 To a solution of acetate derivative (5g, 0.01 mol) in toluene (50ml), piperidine ( 12 ml, 0.25mol, 13.4 eq) was added at room temperature. The reaction mixture was stirred under reflux for 12h. After completion of the reaction, the reaction mixture was worked up to afford the corresponding product (8g).
5 N-CyclopropyI-7-[l ,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-methyl-8-[{2(S)- methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-acetyl heptanoic acid amide (IIIc)
To a solution of acetyl derivative (5g, 0.01 mol) in toluene (50mL), cyclopropylamine (15 ml, 0.4mol, 13.4 eq) was added at room temperature. The reaction mixture was^πrred under reflux for 12h. After compWPion of the reaction, the faction mixture was worked up to afford the corresponding product (7g, 90%).
Example II Preparation of Simvastatin from the corresponding Lovastatin O-TBDMS amide according to schemes I/II
N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8-[{2(S)- methyIbutanoyI}oxy]-l(S)-napthyI]-3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide (VIIIj) A solution of pyrrolidine (4.7mL) .and tetrahydrofuran (20mL) was cooled to
-30°C. A solution of n-butyl lithium (37mL 1.4M) was added keeping the temperature below -20°C (-15 min). After the addition is complete, the mixture was aged at -25°C for 30 minutes. A solution of the amide (5g) in THF (25mL) was charged to the lithium pyrrolidide at -25°C. After the addition is complete, the mixture was agitated for 3 hours at -25 °C. Methyl iodide solution was added (1.6 mL) in one portion and the agitation was continued for a further 30 min at -30°C. The mixture was quenched with water and rapidly agitated for 10 min. The phase was separated and the lower phase was re-extracted with hexane. The combined organic phase was washed with HC1 (IN) and 5% bisulfite syrup, which was used for the next step without any further purification.
The syrup so obtained was dissolved in ethanol (10 mL) at 25°C and a solution of NaOH (1.6g in lOmL of water) was charged. The resulting solution was refluxed and after 3.5hours, the mixture was cooled to 50°C and ethanol was distilled under reduced pressure. The mixture was diluted with water and extracted with ethyl acetate. The combined ethyl acetate layers were back washed with 2% NaOH solution and the organic layer was discarded. The pooled aqueous layer was cooled to 10°C and carefully acidified with 1.5N HC1 to pH=4 in the presence of ethyl acetate. The aqueous layer was re-extracted with ethyl acetate and the combined organic layer was washed with water to neutral pH. To the organic layer 3mL of methanol was added and cooled to 10°C. NH3 gas was bubbled until the precipitation was complete. The mixture was stirred for 30 mTn at 10UC and filtered. The solid was washed with 5 mL of acetone and the product was dried to get the crude product.
The crude product was suspended in water and ethyl acetate was added. The mixture was cooled to 10°C and acidified to pH=4 with 1.5N HCl. The layers were separated and the aqueous layer was re-extracted with ethyl acetate. The combined organic layer was diluted with methanol and the temperature was brought to 20- 23°C. A solution of ammonium hydroxide was added slowly. The mixture was stirred for 1 hour to get complete precipitation and filtered. The precipitate was washed with ethyl acetate and dried to afford the pure product.
The purified ammonium salt was dissolved in 75mL of toluene and heated to 100°C under constant sweep of nitrogen for 6hours. The solution was cooled to 25°C and 1 .25g of activated charcoal and 1.25g of neutral active alumina was added. The mixture was agitated for 30 min. and filtered through celite. The celite pad was washed with toluene (12.5mL). The filtrate was concentrated under reduced pressure to afford a syrup. The syrup was diluted with ethyl acetate and 50 ml of petroleum ether (boiling range 60°C to 80°C) was added. The solution was left for aging for 30 min at 23-25uC. The precipitate obtained was filtered and the solid was washed with petroleum ether and dried at 40°C for 2hours to get the product, simvastatin.
The crude product, (3.5g) was dissolved in methanol (20mL) and 1.25g of activated charcoal was added and stirred for 30min. the mixture was filtered through a celite pad and the celite pad was washed with methanol. To the filtrate water was added slowly till crystallization sets in. The contents were stirred for 0.5h and water (24mL). The contents were stirred for lh and cooled to 15°C. The precipitate was filtered and the solid was washed with 20%o aqueous methanol (l OmL). The solid obtained was dried at 50°C for 4 hours under vacuum to afford the pure title product. The simvastatin obtained was of pharmaceutical grade. N^ropyl-7-[l,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8-[ {2(S)- methyIbutanoyI}oxy]-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-aceryl heptanoic acid amide (IVf) The corresponding lova O-acetyl propyl amide was converted to simvastatin by carrying out the reactions as described in above.
N-PropyI-7-[l,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyI-8-[{2(S)- methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide (IVa)
The corresponding lova O-trifluoroacetyl propyl amide was converted to simvastatin by carrying out the reactions as described in above.
While the invention has been described by reference to specific embodiments, this was for the purpose of illustration only. Numerous alternative embodiments will be apparent to those skilled in the art and are considered within the scope of these claims.

Claims

We claim:
1. A process of manufacturing Simvastatin of formula V from Lovastatin of formula I characterized by the following steps: a. protecting the hydroxy group of the lactone ring of Lovastatin,
- b. converting the protected Lovastatin to Lovastatin amide by treating with an amine in an organic solvent, c. reacting the said lovastatin amide with metal amide base in tetrahydrofuran (THF) followed by treatment with alkyl halide and cooling the said mixture at a temperature ranging between -45°C to -
20°C till C-methylated intermediate compound is formed, d. subjecting the said intermediate compound to hydrolysis to obtain its free acid, e. converting the said free acid to its ammonium salt and cyclizing the said ammonium salt to obtain simvastatin.
2. A process according to claim 1, where the protection of the hydroxy group in the lactone ring is carried out using (RCO) 0 wherein R is CF3 or CH3.
3. A process according to claim 1 , where the protection of the hydroxy group in the lactone ring is carried out using RιR2R3SiCl wherein Ri, R2 and R3 are selected from CH3 and t-Bu.
4. A process according to claim 1 characterized in that said organic solvent is a polar or non-polar solvent.
5. A process according to claim 1 characterized in that said alkyl halide is methyl iodide.
6. A process according to claim 1 characterized in that mixture of lovastatin amide and metal amide base is cooled at -30°C.
7. A process according to claim 1 characterized in that said amine is R4R5NH wherein R4 and R5 is selected from cyclopropyl group, n-Bu, t-Bu, n-Pr or
H.
8. A process according to claim 1 characterized in that said amine is pyrrolidine.
9. A process according to claim 1 characterized in that said amine is piperidine.
10. A process according to claim 1 characterized in that said metal amide base in THF used is prepared by adding n-butyl-lithium to pyrrolidine and cooling at a temperature ranging between -45°C to -20°C.
1 1. A novel intermediate compound [1 S- [ l alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta]-l ,2,3,7,8,8a-hexahydro- 3,7-dimethyl-8-[2-(tetrahydro-4-0-acetyl-6-oxo-2H-pyran-2-yl)ethyl]-l- naphthalenyl ester of formula Ila.
12. A novel intermediate compound [1 S- [l alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta]-l ,2,3,7,8,8a- hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-0-trifluoroacetyl-6-oxo- 2H-pyran-2-yl)ethyl]-l -naphthalenyl ester of formula lib.
13. A novel intermediate compound [1 S-[l alpha(R*),3alpha,7beta,8beta( 2S*,4S*),8abeta]-l ,2,3,7,.8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4- 0-TMS-6-oxo-2H-pyran-2-yl)ethyl]-l -naphthalenyl ester of formula Via.
14. A novel intermediate compound N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-TMS heptanoic acid, amide of formula Vila.
15. A novel intermediate compound N-Butyl-7-[l , 2,6,7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)-
"hydroxy-5(R)-0-TMS heptanoic acid amide of formula Vllb.
16. A novel intermediate compound N-Piperidinyl-7-[ 1 ,2, 6,7,8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]- 3(R)-hydroxy-5(R)-0-TMS heptanoic acid amide of formula Nile. 17. A novel intermediate compound Ν-tert-Butyl-7-[ 1 ,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TMS heptanoic acid amide of formula Vlld.
18. A novel intermediate compound N-Cyclopropyl-7-[l ,2,6,7,8,8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]- 3(R)-hydroxy-5(R)-0-TMS heptanoic acid amide of formula Vile.
19. A novel intermediate compound N-Cyclopropyl-7-[l ,2,6,7,8,8a(R)- hexahydiO-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vllfi
20. A novel intermediate compound N-tert-Butyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vllg.
21. A novel intermediate compound N-Piperidinyl-7-[ 1,2,6,7,8, 8a(R)- hexahy dro-2(S),6(R)-methy l-8-[ { 2(S)-methy lbutanoyl } oxy]- 1 (S)-napthyl]- 3(R)-hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vllh. 22. A novel intermediate compound N-Propyl-7-[ 1 ,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula Vlli. 23. A novel intermediate compound N-Butyl-7-[l,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-TBDMS heptanoic acid amide of formula VIIj.
24. A novel intermediate compound N-Propyl-7-[l ,2,6,7,8^oa(R)-hexanyaro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-acetyl heptanoic acid amide of formula Ilia.
25. A novel intermediate compound N-Butyl-7-[ 1 ,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-acetyl heptanoic acid amide of formula Illb.
26. A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6,7, 8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy-5(R)-0-acetyl heptanoic acid amide of formula IIIc. 27. A novel intermediate compound N-tert-Butyl-7-[ 1,2, 6,7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]~l (S)-napthyl]-3(R)- hydroxy-5(R)-0-acetyl heptanoic acid amide of formula Hid.
28. A novel intermediate compound N-Piperidinyl-7-[l ,2,6,7,8,8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]- 3(R)-hydroxy-5(R)-0-acetyl heptanoic acid amide of formula Hie.
29. A novel intermediate compound N-Propyl-7-[l, 2,6,7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula Hlf.
30. A novel intermediate compound N-Butyl-7-[ 1 ,2,6,7, 8,8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula Illg.
3 1. A novel intermediate compound N-Cyclopropyl-7-[l ,2,6,7, 8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl }oxy]-l (S)-napthyl]- 3(R)-hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula IHh. 32. A novel intermediate compound N-tert-Butyl-7-[ 1 ,2, 6,7,8, 8a(R)-hexahydro- 2(S),6(R)-methyl-8-[{2(S)-methylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula Illi. 33. A novel intermediate compound N-Piperidinyl-7-[ 1 ,2,6,7, 8, 8a(R)- hexahydro-2(S),6(R)-methyl-8-[{2(S)-methylbutanoyI}oxy]-l(S)-napthyl]- 3(R)-hydroxy-5(R)-0-trifluoroacetyl heptanoic acid amide of formula IIIj.
34. A novel intermediate compound N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl }oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVa.
35. A novel intermediate compound N-Butyl-7-[ l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-3 (S)-napthyl]-3(R)- h\'droxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVb.
36. A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6, 7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]- l(S napthyl]-3(R)-hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVc.
37. A novel intermediate compound N-tert-Butyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2( S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVd.
38. A novel intermediate compound N-Piperidinyl-7-[ 1,2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)- napthyl]-3(R)-hydroxy,5(R)-0-trifluoroacetylheptanoic acid amide of formula IVe.
39. A novel intermediate compound N-Propyl-7-[ 1,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVf.
40. A novel intermediate compound N-Butyl-7-[l,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVg.
41 . A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2~dimethylbutanoyl } oxy]- 1 (S)- napthyl]-3(R)-hydroxy,5(R)-0-acetylheptanoic acid amide of formula I Vh.
42. A novel intermediate compound N-tert-Butyl-7-[ 1,2,6,7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R hydroxy, 5(R)-0-acetylheptanoic acid amide of formula IVi.
43. A novel intermediate compound N-Piperdinyl-7-[ 1 ,2,6,^8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]- l (S)-napthyl]-3(R)- hydroxy,5(R)-0-acetylheptanoic acid amide of formula IVj.
44. A novel intermediate compound N-Piperidinyl-7-[l ,2,6,7, 8,8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]- l (S)- napthyl]-3(R)-hydroxy,5(R)-0~TMS heptanoic acid amide of formula Villa.
45. A novel intermediate compound N-tert-Butyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy,5(R)-0-TMS heptanoic acid amide of formula VIHb. 46. A novel intermediate compound N-Cyclopropyl-7-[ 1,2,6, 7,8,8a(R)- hexahydiO-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)- napthyl]-3(R)-hydroxy,5(R)-0-TMS heptanoic acid amide of formula VIIIc.
47. A novel intermediate compound N-Butyl-7-[ 1 ,2, 6,7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy, 5(R)-0-TMS heptanoic acid amide of formula VIHd.
48. A novel intermediate compound N-Propyl-7~[ 1,2,6,7, 8, 8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- hydroxy,5(R)-0-TMS heptanoic acid amide of formula VHIe.
49. A novel intermediate compound N-Piperidinyl-7-[ 1 ,2, 6,7,8, 8a(R)- hexahydro-2(S),6(R)-dimethy l-8(S)-[2,2-dimethylbutanoy 1 } oxy]- 1 (S)- napthyl]-3(R)-hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula Vlllf.
50. A novel intermediate compound N-tert-Butyl-7-[l ,2,6,7, 8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l (S)-napthyl]-3(R)- hydroxy, 5 (R)-O-TBDMS heptanoic acid amide of formula Vlllg.
51. A novel intermediate compound N-Cyclopropyl-7-[ 1 ,2,6,7,8,8a(R)- hexahydro-2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)- napthyl]-3(R)-hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula VHIh.
52., ; A novel intermediate compound N-Butyl-7-[ 1 ,2,6, 7,8, 8a(R)-hexahydro- 2(S),6(R)-dimethy l-8(S)-[2,2-dimethy lbutanoy 1 } oxy]- 1 (S)-napthyl]-3(R)- hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula VIHi.
53. A novel intermediate compound N-Propyl-7-[l ,2,6,7,8,8a(R)-hexahydro- 2(S),6(R)-dimethyl-8(S)-[2,2-dimethylbutanoyl}oxy]-l(S)-napthyl]-3(R)- "hydroxy,5(R)-0-TBDMS heptanoic acid amide of formula VIIIj.
PCT/IN2000/000088 2000-09-13 2000-09-13 Process for manufacturing simvastatin and the novel intermediates WO2002024675A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001228796A AU2001228796A1 (en) 2000-09-13 2000-09-13 Process for manufacturing simvastatin and the novel intermediates
PCT/IN2000/000088 WO2002024675A1 (en) 2000-09-13 2000-09-13 Process for manufacturing simvastatin and the novel intermediates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2000/000088 WO2002024675A1 (en) 2000-09-13 2000-09-13 Process for manufacturing simvastatin and the novel intermediates

Publications (1)

Publication Number Publication Date
WO2002024675A1 true WO2002024675A1 (en) 2002-03-28

Family

ID=11076270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2000/000088 WO2002024675A1 (en) 2000-09-13 2000-09-13 Process for manufacturing simvastatin and the novel intermediates

Country Status (2)

Country Link
AU (1) AU2001228796A1 (en)
WO (1) WO2002024675A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118300A1 (en) * 2006-04-19 2007-10-25 Jean Paul Dupuis Offering bets on events during a live event while the live event is in progress
CN101747357B (en) * 2008-12-11 2012-07-25 北大方正集团有限公司 Method for preparing simvastatin intermediate - simva-acylamide second silicon ether

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5763653A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5763653A (en) * 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118300A1 (en) * 2006-04-19 2007-10-25 Jean Paul Dupuis Offering bets on events during a live event while the live event is in progress
CN101747357B (en) * 2008-12-11 2012-07-25 北大方正集团有限公司 Method for preparing simvastatin intermediate - simva-acylamide second silicon ether

Also Published As

Publication number Publication date
AU2001228796A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
EP0864569B1 (en) Process for manufacturing simvastatin from lovastatin or mevinolinic acid
US4820850A (en) Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5393893A (en) Process for producing simvastatin and analogs thereof
JP5048709B2 (en) Method for producing simvastatin
US5763653A (en) Key intermediates in the manufacture of simvastatin
US6252091B1 (en) Process for the preparation of simvastatin and derivatives thereof
AU759878B2 (en) Process for producing simvastatin and/or its derivatives
EP0349063A2 (en) 5-oxygenated HMG-COA reductase inhibitors
EP1480943A2 (en) Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
WO2002024675A1 (en) Process for manufacturing simvastatin and the novel intermediates
US6573392B1 (en) Process for manufacturing simvastatin and the novel intermediates
SK283319B6 (en) Process for manufacturing simvastatin from lovastatin or mevinolinic acid
EP0137444A2 (en) Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-Decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
EP0306263B1 (en) Novel hmg-coa reductase inhibitors
Kant Belwal et al. Synthetic methods for simvastatin–An overview
KR100503923B1 (en) Intermediates in Simvastatin Production
WO2006072963A1 (en) Process for preparing simvastatin from lovastatin amine salts in three steps
CZ264997A3 (en) Process for preparing simvastatin from lovostatin or mevinolinic acid
WO2007096753A2 (en) Process for preparing highly pure simvastatin
WO2005069741A2 (en) Process for producing simvastatin using novel hydrazide intermediates
KR20040092790A (en) Method of Preparing Statins Intermediates
KR20030040858A (en) Preparation of simvastatin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP